Company intelligence / Profile preview

Promedior

Lexington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics for the treatment of fibrosis. The company's lead product candidate, PRM-151 (zinpentraxin alfa), is a recombinant form of the endogenous human protein pentraxin-2 that prevents and reverses fibrosis by modulating monocyte differentiation. Promedior's pipeline targets a broad range of systemic fibrotic diseases, including idiopathic pulmonary fibrosis and myelofibrosis. In 2020, the company was acquired by Roche for an upfront payment of $390 million plus potential milestone payments totaling up to $1 billion.

Therapeutic areas: HematologyPulmonology
Modalities: Recombinant proteinBiologic
Industry: Biotech

Partnerships

RocheBristol Myers Squibb

Beyond the preview

Go deeper on Promedior.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promedior.

Explore the full profile